As 2024 winds down and the number of FDA-approved medical devices packing AI approaches 1,000—the agency had the tally at 950 as of August—the industry finds itself at a “critical inflection point.” 

The groups are urging the Supreme Court to uphold a lower court ruling in Garland v. VanDerStok that permits the ATF to regulate firearms made from part kits. 

The agency has received an increasing number of complaints from patients enrolled in a low-value health plan without their knowledge. If finalized, a new rule would empower CMS to ban brokers from the ACA marketplace. 

Early data suggest the drug, an oral lipoprotein (a) disruptor, could make a significant impact on patient care. AstraZeneca will pay $100 million upfront, with much more to follow if certain milestones are met. 

The new report could go on to help guide decisions made by CMS and hospital leadership teams for years to come.

The administration is seeking greater communication between the manufacturers of breakthrough devices and physician professional societies such as the ACR. 

Founded in 2019, the firm is focused on developing products for the diagnosis and therapy of blood cancers and other indications not addressed by nuclear medicine. 

TPG will not own a majority of the e-prescriber, with CVS Health and Express Scripts maintaining a minority stake.